Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1982 1
1984 1
1987 2
1988 2
1990 4
1991 4
1992 2
1993 4
1994 3
1995 5
1996 4
1997 4
1998 1
1999 3
2000 5
2001 5
2002 4
2003 3
2004 3
2005 3
2006 3
2007 4
2008 3
2009 4
2010 1
2011 2
2012 2
2014 1
2015 2
2016 1
2017 3
2018 1
2019 2
2021 1
2022 2
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

98 results

Results by year

Filters applied: . Clear all
Page 1
B and T cell prolymphocytic leukaemia.
Cross M, Dearden C. Cross M, et al. Best Pract Res Clin Haematol. 2019 Sep;32(3):217-228. doi: 10.1016/j.beha.2019.06.001. Epub 2019 Jun 6. Best Pract Res Clin Haematol. 2019. PMID: 31585622 Review.
Prolymphocytic leukaemias B-PLL and T-PLL are rare disorders, typically with an aggressive clinical course and poor prognosis. ...Disruption of TP53 is a key finding, conveying chemotherapy resistance requiring novel therapies such as B-cell receptor inhibito …
Prolymphocytic leukaemias B-PLL and T-PLL are rare disorders, typically with an aggressive clinical course and poor prognosis. ...Dis …
Prolymphocytic leukemia.
Absi A, Hsi E, Kalaycio M. Absi A, et al. Curr Treat Options Oncol. 2005 May;6(3):197-208. doi: 10.1007/s11864-005-0003-4. Curr Treat Options Oncol. 2005. PMID: 15869731 Review.
Prolymphocytic leukemia is a rare chronic lymphoproliferative disorder that includes two subtypes, B cell and T cell, each with its own distinct clinical, laboratory and pathological features. ...We recommend alemtuzumab as initial therapy and offer st …
Prolymphocytic leukemia is a rare chronic lymphoproliferative disorder that includes two subtypes, B cell and T …
B-prolymphocytic leukemia: Is it time to retire this entity?
El Hussein S, Khoury JD, Medeiros LJ. El Hussein S, et al. Ann Diagn Pathol. 2021 Oct;54:151790. doi: 10.1016/j.anndiagpath.2021.151790. Epub 2021 Jul 16. Ann Diagn Pathol. 2021. PMID: 34293709 Review.
B-prolymphocytic leukemia (B-PLL) is included as a distinct entity in the current World Health Organization classification of hematolymphoid neoplasms. ...These data have shown that many B-PLL cases present many similarities with other types of small B-cel …
B-prolymphocytic leukemia (B-PLL) is included as a distinct entity in the current World Health Organization classification of …
Prolymphocytic leukemias.
Krishnan B, Matutes E, Dearden C. Krishnan B, et al. Semin Oncol. 2006 Apr;33(2):257-63. doi: 10.1053/j.seminoncol.2006.01.015. Semin Oncol. 2006. PMID: 16616073 Review.
T and B subtypes of prolymphocytic leukemias (PLLs) are rare, highly aggressive lymphoid malignancies with characteristic morphologic, immunophenotypical, cytogenetic, and molecular features. Recent studies have highlighted the role of specific oncogenes such as TCL1, MTCP …
T and B subtypes of prolymphocytic leukemias (PLLs) are rare, highly aggressive lymphoid malignancies with characteristic morphologic …
Alemtuzumab.
Frampton JE, Wagstaff AJ. Frampton JE, et al. Drugs. 2003;63(12):1229-43; discussion 1245-6. doi: 10.2165/00003495-200363120-00003. Drugs. 2003. PMID: 12790693 Review.
Alemtuzumab is an unconjugated, humanised, monoclonal antibody directed against the cell surface antigen CD52 on lymphocytes and monocytes. In noncomparative phase I/II studies in patients with B-cell chronic lymphocytic leukaemia (B-CLL) relapsed after or refractor …
Alemtuzumab is an unconjugated, humanised, monoclonal antibody directed against the cell surface antigen CD52 on lymphocytes and monocytes. …
Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment.
Collignon A, Wanquet A, Maitre E, Cornet E, Troussard X, Aurran-Schleinitz T. Collignon A, et al. Curr Oncol Rep. 2017 Apr;19(4):29. doi: 10.1007/s11912-017-0581-x. Curr Oncol Rep. 2017. PMID: 28324286 Review.
RECENT FINDINGS: B cell prolymphocytic leukemia (B-PLL) diagnosis remains challenging in the absence of clear immunophenotypic or cytogenetic signature and overlap with mantle cell lymphoma. New molecular defects have been identified in T cell proly …
RECENT FINDINGS: B cell prolymphocytic leukemia (B-PLL) diagnosis remains challenging in the absence of clear im …
Clinical features and diagnosis of hairy cell leukemia.
Quest GR, Johnston JB. Quest GR, et al. Best Pract Res Clin Haematol. 2015 Dec;28(4):180-92. doi: 10.1016/j.beha.2015.10.017. Epub 2015 Oct 26. Best Pract Res Clin Haematol. 2015. PMID: 26614896 Review.
Significant advances in the diagnosis and treatment of hairy cell leukemia (HCL) have recently been made. Improved distinction of HCL from its mimics though clinical presentations, morphologic and immunophenotypic features, and more recently molecular biology, has highligh …
Significant advances in the diagnosis and treatment of hairy cell leukemia (HCL) have recently been made. Improved distinction of HCL …
Prolymphocytic leukemia.
Stone RM. Stone RM. Hematol Oncol Clin North Am. 1990 Apr;4(2):457-71. Hematol Oncol Clin North Am. 1990. PMID: 2182602 Review.
PLL is an unusual clinical and morphologic variant of CLL which, in the more common B cell version, represents malignant transformation of a B lymphocyte at an intermediate stage of development. The immunophenotype of PLL cells, characterized by heavy cell surface s …
PLL is an unusual clinical and morphologic variant of CLL which, in the more common B cell version, represents malignant trans …
B- and T-cell prolymphocytic leukemia: antibody approaches.
Dearden C. Dearden C. Hematology Am Soc Hematol Educ Program. 2012;2012:645-51. doi: 10.1182/asheducation-2012.1.645. Hematology Am Soc Hematol Educ Program. 2012. PMID: 23233647 Review.
B- and T-cell subtypes of prolymphocytic leukemia (PLL) are rare, aggressive lymphoid malignancies with characteristic morphologic, immunophenotypic, cytogenetic, and molecular features. ...TP53 abnormalities are common and, as for chronic lymphocytic leukemia …
B- and T-cell subtypes of prolymphocytic leukemia (PLL) are rare, aggressive lymphoid malignancies with characteristic morphol …
p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell.
Tessoulin B, Eveillard M, Lok A, Chiron D, Moreau P, Amiot M, Moreau-Aubry A, Le Gouill S, Pellat-Deceunynck C. Tessoulin B, et al. Blood Rev. 2017 Jul;31(4):251-259. doi: 10.1016/j.blre.2017.03.001. Epub 2017 Mar 4. Blood Rev. 2017. PMID: 28284458 Review.
We describe here the p53 landscape in B-cell malignancies, from B-Acute Lymphoblastic Leukemia to Plasma Cell Leukemia, by analyzing incidence of gain or loss of function of actors both upstream and within the p53 pathway, namely MYC, RAS, ARF, MDM2, A …
We describe here the p53 landscape in B-cell malignancies, from B-Acute Lymphoblastic Leukemia to Plasma Cell Leukem …
98 results